The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam

Fundamental and Clinical Pharmacology

Volumn 10, Issue 3, 1996, Pages 314-318

  Ahonen, J ^a   Olkkola, K T ^a   Neuvonen, P J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Diazepam; Interaction; Itraconazole; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTIFUNGAL AGENT; CYTOCHROME P450 INHIBITOR; DIAPAM; DIAZEPAM; ITRACONAZOLE; MIDAZOLAM; PLACEBO; TRIAZOLAM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 0029906407     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1996.tb00312.x     Document Type: Article

References (21)

1. Allenmark S, Edebo A, Lingren K. Determination of itraconazole in serum with high-performance liquid chromatography and fluorecence detection. J Chromatogr 1990;532: 203-6
2. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991;21:195-212
3. Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994;38:131-7
4. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991;32:624-6
5. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-55
6. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4
7. Dasberg HM. Effects and plasma concentrations of desmethyl-diazepam after oral administration in normal volunteers. Psychopharmacologia 1975;43:191-8
8. De Kroon IFI, Langendijk PNJ, De Goede PNFC. Simultaneous determination of midazolam and its three hydroxy metabolites in human plasma by electron-capture gas chromatography without derivatization. J Chromatogr 1989;491: 107-16
9. Dollery C, ed. Therapeutic Drugs. London: Churchill Livingstone, 1991;86-91
10. Greenblatt DJ, Harmatz JS, Shader RI. Factors influencing diazepam pharmacokinetics: age, sex and liver disease. Int J Clin Pharmacol 1978;19:177-9
11. Greenblatt DJ, Divoll MK, Soong MH, Boxenbaum HG, Harmatz JS, Shatter RI. Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam and clorazepate, and intravenous diazepam. J Clin Pharmacol 1988;28:853-9
12. 3-hydroxylation. Drug Metab Dispos 1988;16:605-8
13. Jack ML, Colburn WA. Pharmacokinetic model for diazepam and its major metabolite desmethyldiazepam following diazepam administration. J Pharm Sci 1983;73:1318-23
14. Kato R, Yamazoe Y. The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics 1994;4:359-62
15. Klotz U, Reimann I. Delayed clearance of diazepam due to cimetidine. New Engl J Med 1980;302:1012-4
16. Ohnhaus EE, Park BK, Colombo JP, Heitzman JP. The effect of enzyme induction on diazepam metabolism in man. Br J Clin Pharmacol 1979;8:557-63
17. Olkkola KT, Backman J, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther 1994;55:481-5
18. Perruca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M, Bialer M. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56:471-6
19. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen PJ. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45:191-3
20. Rall TW. Hypnotics and sedatives; ethanol. In: Goodman and Gilman's. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1992;353
21. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56:601-7